Consequently, the lower frequency of the AA haplotype in the Chilean population may influence drug responses and toxicity profiles, particularly in the context of AML, potentially impacting treatment outcomes for conditions influenced by ABCB1 functionality. The gene discussed is ABCB1; the disease is acute myeloid leukemia.